Cargando…
Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study
Aim: To examine the effect of subthreshold micropulse yellow laser (SMYL) on best-corrected visual acuity (BCVA), central macular thickness (CMT), and optical coherence tomography angiography (OCT-A) changes in eyes with persistent diabetic macular edema (DME) after pars plana vitrectomy (PPV) for t...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019565/ https://www.ncbi.nlm.nih.gov/pubmed/35462889 http://dx.doi.org/10.3389/fphar.2022.832448 |
_version_ | 1784689314335031296 |
---|---|
author | Bonfiglio, Vincenza Rejdak, Robert Nowomiejska, Katarzyna Zweifel, Sandrine Anne Justus Wiest, Maximilian Robert Romano, Giovanni Luca Bucolo, Claudio Gozzo, Lucia Castellino, Niccolò Patane, Clara Pizzo, Corrado Reibaldi, Michele Russo, Andrea Longo, Antonio Fallico, Matteo Macchi, Iacopo Vadalà, Maria Avitabile, Teresio Costagliola, Ciro Jonak, Kamil Toro, Mario Damiano |
author_facet | Bonfiglio, Vincenza Rejdak, Robert Nowomiejska, Katarzyna Zweifel, Sandrine Anne Justus Wiest, Maximilian Robert Romano, Giovanni Luca Bucolo, Claudio Gozzo, Lucia Castellino, Niccolò Patane, Clara Pizzo, Corrado Reibaldi, Michele Russo, Andrea Longo, Antonio Fallico, Matteo Macchi, Iacopo Vadalà, Maria Avitabile, Teresio Costagliola, Ciro Jonak, Kamil Toro, Mario Damiano |
author_sort | Bonfiglio, Vincenza |
collection | PubMed |
description | Aim: To examine the effect of subthreshold micropulse yellow laser (SMYL) on best-corrected visual acuity (BCVA), central macular thickness (CMT), and optical coherence tomography angiography (OCT-A) changes in eyes with persistent diabetic macular edema (DME) after pars plana vitrectomy (PPV) for tractional DME (TDME). Patients and Methods: In a comparative study, 95 eyes of 95 consecutive patients with persistent DME were prospectively enrolled. The SMYL group (54 eyes) was treated with SMYL 6 months after PPV, while the control group (41 eyes) was followed up without treatment. BCVA and CMT by OCT were analyzed at baseline and 3 and 6 months. Additionally, parameters such as the vessel density (VD) in the superficial capillary plexus (SCP) and deep capillary plexus (DCP), respectively, and the area of the foveal avascular zone (FAZ) were also evaluated on OCT-A. Results: There were no significant differences between both groups in demographic data. In the SMYL group, mean BCVA was significantly increased [F(2,106) = 17.25; p < 0.001; [Formula: see text] = 0.246] from 51.54 ± 13.81 ETDRS letters at baseline to 57.81 ± 12.82 ETDRS letters at 3 months (p < 0.001) and 57.83 ± 13.95 EDTRS letters at 6 months (p < 0.001), respectively. In comparison to the control group, BCVA values were statistically significantly higher in the SMYL group at 3 and 6 months, respectively. Mean CMT significantly decreased [F(2,106) = 30.98; p < 0.001; [Formula: see text] = 0.368] from the baseline value 410.59 ± 129.91 μm to 323.50 ± 89.66 μm at 3 months (p < 0.001) and to 283.39 ± 73.45 μm at 6 months (p < 0.001). CMT values were significantly lower in the SMYL group (p < 0.001), especially at 6 months follow-up time (p < 0.001) compared with the control group. Parafoveal VD in the SCP and DCP was significantly higher in the SMYL group in comparison to the control group, respectively, at 3-month (SCP p < 0.001; DCP p < 0.001) and 6-month follow-up (SCP p < 0.001; DCP p < 0.001). FAZ area was also significantly smaller in the SMYL group at 6-month follow-up (p = 0.001). There were no adverse SMYL treatment effects. Conclusion: SMYL therapy may be a safe and effective treatment option in eyes with persistent macular edema following PPV for TDME. |
format | Online Article Text |
id | pubmed-9019565 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90195652022-04-21 Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study Bonfiglio, Vincenza Rejdak, Robert Nowomiejska, Katarzyna Zweifel, Sandrine Anne Justus Wiest, Maximilian Robert Romano, Giovanni Luca Bucolo, Claudio Gozzo, Lucia Castellino, Niccolò Patane, Clara Pizzo, Corrado Reibaldi, Michele Russo, Andrea Longo, Antonio Fallico, Matteo Macchi, Iacopo Vadalà, Maria Avitabile, Teresio Costagliola, Ciro Jonak, Kamil Toro, Mario Damiano Front Pharmacol Pharmacology Aim: To examine the effect of subthreshold micropulse yellow laser (SMYL) on best-corrected visual acuity (BCVA), central macular thickness (CMT), and optical coherence tomography angiography (OCT-A) changes in eyes with persistent diabetic macular edema (DME) after pars plana vitrectomy (PPV) for tractional DME (TDME). Patients and Methods: In a comparative study, 95 eyes of 95 consecutive patients with persistent DME were prospectively enrolled. The SMYL group (54 eyes) was treated with SMYL 6 months after PPV, while the control group (41 eyes) was followed up without treatment. BCVA and CMT by OCT were analyzed at baseline and 3 and 6 months. Additionally, parameters such as the vessel density (VD) in the superficial capillary plexus (SCP) and deep capillary plexus (DCP), respectively, and the area of the foveal avascular zone (FAZ) were also evaluated on OCT-A. Results: There were no significant differences between both groups in demographic data. In the SMYL group, mean BCVA was significantly increased [F(2,106) = 17.25; p < 0.001; [Formula: see text] = 0.246] from 51.54 ± 13.81 ETDRS letters at baseline to 57.81 ± 12.82 ETDRS letters at 3 months (p < 0.001) and 57.83 ± 13.95 EDTRS letters at 6 months (p < 0.001), respectively. In comparison to the control group, BCVA values were statistically significantly higher in the SMYL group at 3 and 6 months, respectively. Mean CMT significantly decreased [F(2,106) = 30.98; p < 0.001; [Formula: see text] = 0.368] from the baseline value 410.59 ± 129.91 μm to 323.50 ± 89.66 μm at 3 months (p < 0.001) and to 283.39 ± 73.45 μm at 6 months (p < 0.001). CMT values were significantly lower in the SMYL group (p < 0.001), especially at 6 months follow-up time (p < 0.001) compared with the control group. Parafoveal VD in the SCP and DCP was significantly higher in the SMYL group in comparison to the control group, respectively, at 3-month (SCP p < 0.001; DCP p < 0.001) and 6-month follow-up (SCP p < 0.001; DCP p < 0.001). FAZ area was also significantly smaller in the SMYL group at 6-month follow-up (p = 0.001). There were no adverse SMYL treatment effects. Conclusion: SMYL therapy may be a safe and effective treatment option in eyes with persistent macular edema following PPV for TDME. Frontiers Media S.A. 2022-04-06 /pmc/articles/PMC9019565/ /pubmed/35462889 http://dx.doi.org/10.3389/fphar.2022.832448 Text en Copyright © 2022 Bonfiglio, Rejdak, Nowomiejska, Zweifel, Justus Wiest, Romano, Bucolo, Gozzo, Castellino, Patane, Pizzo, Reibaldi, Russo, Longo, Fallico, Macchi, Vadalà, Avitabile, Costagliola, Jonak and Toro. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Bonfiglio, Vincenza Rejdak, Robert Nowomiejska, Katarzyna Zweifel, Sandrine Anne Justus Wiest, Maximilian Robert Romano, Giovanni Luca Bucolo, Claudio Gozzo, Lucia Castellino, Niccolò Patane, Clara Pizzo, Corrado Reibaldi, Michele Russo, Andrea Longo, Antonio Fallico, Matteo Macchi, Iacopo Vadalà, Maria Avitabile, Teresio Costagliola, Ciro Jonak, Kamil Toro, Mario Damiano Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study |
title | Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study |
title_full | Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study |
title_fullStr | Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study |
title_full_unstemmed | Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study |
title_short | Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study |
title_sort | efficacy and safety of subthreshold micropulse yellow laser for persistent diabetic macular edema after vitrectomy: a pilot study |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019565/ https://www.ncbi.nlm.nih.gov/pubmed/35462889 http://dx.doi.org/10.3389/fphar.2022.832448 |
work_keys_str_mv | AT bonfigliovincenza efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT rejdakrobert efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT nowomiejskakatarzyna efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT zweifelsandrineanne efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT justuswiestmaximilianrobert efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT romanogiovanniluca efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT bucoloclaudio efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT gozzolucia efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT castellinoniccolo efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT pataneclara efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT pizzocorrado efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT reibaldimichele efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT russoandrea efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT longoantonio efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT fallicomatteo efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT macchiiacopo efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT vadalamaria efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT avitabileteresio efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT costagliolaciro efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT jonakkamil efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy AT toromariodamiano efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy |